Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (41-50 of 310) with videos related to

Pageof 31
Sort By:
Diabetes Care|February 15, 2008
Albuminuria: a great risk marker, but an underestimated target in diabetesDick de Zeeuw, Itamar Raz
Diabetes Care|July 25, 2013
Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)Stefano Del Prato, Itamar Raz
Diabetes Care|October 31, 2009
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? NoSameer A Kassem, Itamar Raz
Expert Opinion on Pharmacotherapy|March 6, 2019
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetesGenya Aharon-Hananel, Itamar Raz
Diabetes Care|April 29, 2011
Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): outcome studies versus clinical experience in the treatment of diabetesItamar Raz, Stefano Del Prato
Diabetes Care|July 22, 2016
Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes CouncilOfri Mosenzon, Rena Pollack, Itamar Raz
Diabetes Care|July 22, 2016
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOSGuntram Schernthaner, Avivit Cahn, Itamar Raz
Trends in Biotechnology|March 1, 2005
Immune modulation for prevention of type 1 diabetes mellitusItamar Raz, Roy Eldor, Yaakov Naparstek
Diabetes/Metabolism Research and Reviews|March 10, 2009
Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial resultsRoy Eldor, Sameer Kassem, Itamar Raz
Expert Opinion on Emerging Drugs|November 5, 2016
An update on DPP-4 inhibitors in the management of type 2 diabetesAvivit Cahn, Simona Cernea, Itamar Raz
Pageof 31

Showing results (41-50 of 310) with videos related to

Sort By:
Pageof 31
Diabetes Care|February 15, 2008
Albuminuria: a great risk marker, but an underestimated target in diabetesDick de Zeeuw, Itamar Raz
Diabetes Care|July 25, 2013
Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)Stefano Del Prato, Itamar Raz
Diabetes Care|October 31, 2009
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? NoSameer A Kassem, Itamar Raz
Expert Opinion on Pharmacotherapy|March 6, 2019
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetesGenya Aharon-Hananel, Itamar Raz
Diabetes Care|April 29, 2011
Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): outcome studies versus clinical experience in the treatment of diabetesItamar Raz, Stefano Del Prato
Diabetes Care|July 22, 2016
Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes CouncilOfri Mosenzon, Rena Pollack, Itamar Raz
Diabetes Care|July 22, 2016
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOSGuntram Schernthaner, Avivit Cahn, Itamar Raz
Trends in Biotechnology|March 1, 2005
Immune modulation for prevention of type 1 diabetes mellitusItamar Raz, Roy Eldor, Yaakov Naparstek
Diabetes/Metabolism Research and Reviews|March 10, 2009
Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial resultsRoy Eldor, Sameer Kassem, Itamar Raz
Expert Opinion on Emerging Drugs|November 5, 2016
An update on DPP-4 inhibitors in the management of type 2 diabetesAvivit Cahn, Simona Cernea, Itamar Raz
Pageof 31